Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapirolizumab pegol placental transfer study in pregnant women with active systemic lupus erythematosus
NL-OMON61678Phase 1Not yet recruiting
- Sponsor
- UCB
- Start
- Jan 2027
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dapirolizumab pegol in systemic lupus erythematosus (SLE), sponsored by UCB. Primary endpoints: Infant plasma concentration of dapirolizumab pegol at birth, Maternal plasma concentration of dapirolizumab pegol at delivery and 1 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
dapirolizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON61678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61678.